Smarter API Synthesis For Cost Optimization

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

My name is Dr. Sanjay Shukla, and I have spent more than 22 years in synthetic organic chemistry. With a Ph.D. and a deep background in pharmaceutical R&D, my career has centered around API process development, CDMO/CRAMS operations, and technology transfer.

My journey began at Zydus Cadila and Dr. Reddy’s Laboratories, where I focused on process chemistry for important generic APIs—including treatments for Alzheimer’s disease, asthma, and dyslipidemia—and contributed to several patents. I later joined Lupin Laboratories, where I took on tech transfer projects for antihypertensive and cephalosporin drugs. After that, I spent 14 years at Suven Pharmaceuticals as Deputy General Manager – R&D, where I led teams of M.Sc. and Ph.D. scientists. During my time there, I oversaw the development and scale-up of more than 100 APIs and advanced intermediates for major global companies such as Pfizer, BMS, Bayer, Astellas, Teva, and Sumitomo, spanning therapeutic areas including CNS, cardiovascular, anti-infectives, and antivirals.

My main strength is designing innovative, non-infringing, and cost-effective synthetic routes—from initial lab concepts to commercial-scale manufacturing. I place special emphasis on impurity profiling, genotoxic …